BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE

被引：0
|
作者：
Tosi, P. [1 ]
Zamagni, E. [1 ]
Tacchetti, P. [1 ]
Perrone, G. [1 ]
Ceccolini, M. [1 ]
Brioli, A. [1 ]
Pallotti, M. [1 ]
Pantani, L. [1 ]
Petrucci, A. [1 ]
Baccarani, M. [1 ]
Cavo, M. [1 ]
机构：
[1] Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0659
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [31] Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Brioli, Annamaria
    Perrone, Giulia
    Volpe, Silvestro
    Pasini, Silvana
    Mele, Anna
    Rossini, Fausto
    Liberati, Anna Marina
    De Rosa, Luca
    Avvisati, Giuseppe
    Amadori, Sergio
    Gozzetti, Alessandro
    Capaldi, Antonio
    Mele, Giuseppe
    Farina, Giuliana
    Zamagni, Elena
    Vigna, Ernesto
    Capalbo, Silvana
    Magni, Michele
    Nunziata, Giuseppe Rodolfo
    Crugnola, Monica
    Fregoni, Vittorio
    Leopardi, Giuliana
    Attolico, Immacolata
    Moscetti, Alessandro
    Podda, Luigi
    Pregno, Patrizia
    Baccarani, Michele
    Cavo, Michele
    BLOOD, 2011, 118 (21) : 148 - 148
  • [32] First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
    Tosi, P
    Zamagni, E
    Cellini, C
    Parente, R
    Cangini, D
    Tacchetti, P
    Perrone, G
    Ceccolini, M
    Boni, P
    Tura, S
    Baccarani, M
    Cavo, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (05) : 399 - 404
  • [33] VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.
    Alexaman, R
    Wang, LM
    Weber, DM
    Delasalle, KB
    BLOOD, 2004, 104 (11) : 64A - 64A
  • [34] Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma
    Mark, Tomer M.
    Bowman, Isaac A.
    Rossi, Adriana C.
    Shah, Manan
    Rodriguez, Melissa
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2842 - 2849
  • [35] Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
    Leiba, Merav
    Kedmi, Meirav
    Duek, Adrian
    Freidman, Tzachi
    Weiss, Mia
    Leiba, Ronit
    Nagler, Arnon
    Avigdor, Abraham
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 702 - 710
  • [36] Should thaldex (thalidomide-dexamethasone) replace VAD (vincristine-adriamycin-dexamethasone) as induction treatment for newly diagnosed multiple myeloma? The Indian perspective
    Pandey, Ritwik
    Patel, Kirti M.
    Shah, Sandip A.
    Patel, Apurva A.
    ANNALS OF ONCOLOGY, 2007, 18 : 181 - 181
  • [37] Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
    Wu, Shenghao
    Zheng, Cuiping
    Chen, Songyan
    Cai, Xiaoping
    Shi, Yuejian
    Lin, Bijing
    Chen, Yuemiao
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [38] Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma in Chinese patients
    Cai, Zhen
    Zheng, Weiyan
    Wei, Guoqing
    Ye, Xiujin
    He, Jingsong
    Li, Li
    Wu, Wenjun
    Lin, Maofang
    BLOOD, 2007, 110 (11) : 281B - 281B
  • [39] Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience
    Zheng, Weiyan
    Wei, Guoqing
    Ye, Xiujin
    He, Jingsong
    Li, Li
    Wu, Wenjun
    Shi, Jimin
    Zhang, Jie
    Huang, Weijia
    Xie, Wanzhuo
    Luo, Yi
    Xue, Xingkui
    Lin, Maofang
    Huang, He
    Cai, Zhen
    LEUKEMIA RESEARCH, 2009, 33 (12) : 1615 - 1618
  • [40] INDUCTION THERAPY WITH BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTD) DOES NOT IMPAIRE AUTOLOGOUS PERIPHERAL BLOOD STEM-CELL (PBSC) COLLECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Brioli, A.
    Perrone, G.
    Galli, M.
    Di Raimondo, F.
    Bringhen, S.
    Motta, M. R.
    Montefusco, V.
    Spadano, T.
    Pescosta, N.
    Ledda, A.
    Falcone, A.
    Pezzi, A.
    Zambello, R.
    Gherlinzoni, F.
    Zannetti, B.
    Ballanti, S.
    Petti, M.
    Marcatti, M.
    Rizzi, S.
    Nozza, A.
    Califano, C.
    Baccarani, M.
    Cavo, M.
    HAEMATOLOGICA, 2012, 97 : 177 - 178
12345